跳至主要内容
临床试验/NCT01901601
NCT01901601撤回不适用

Randomized Clinical Trial of OCT-Guided Laser-Assisted Lamellar Anterior Keratoplasty in Adults for Stromal Opacities

Oregon Health and Science University0 个研究点开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
主要终点
BSCVA (Snellen chart)

研究概览

简要总结

The purpose of this protocol is to compare and develop new surgical technique of partial-thickness corneal transplantation for treating corneal opacity. A newly developed technique, "dovetail" laser-assisted lamellar anterior keratoplasty (LALAK), will be tested and compared with standard full-thickness corneal transplantation, Intralase-enabled keratoplasty (IEK). The new LALAK technique replaces only the front portion of the cornea and does not have the risks associated with conventional IEK. Additionally, optical coherence tomography (OCT) will be used to guide the depth of the graft and donor dissections.

The data will be analyzed to understand whether the new technique (LALAK) can repeatedly achieve good visual outcomes with lower risk from the operation compared to the visual outcomes and risk associated with the current standard of care, IEK.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eyes with corneal opacities that cannot be adequately or safely corrected with spectacles, contact lens or excimer laser surface ablation. The cornea must have healthy endothelium (endothelial cell density > 1,500/mm2).

排除标准

  • Preoperative corneal thickness less than 400 microns.
  • Inability to give informed consent.
  • Corneal edema
  • Central guttata
  • Inability to maintain stable fixation for OCT imaging.
  • Inability to commit to required visits to complete the study.
  • Eyes with concurrent cataract, retinal diseases, glaucoma, or other eye conditions that may limit the visual outcome after surgery.
  • Patients with severe collagen vascular diseases or ocular surface disorders

研究组 & 干预措施

LALAK

Experimental

laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.

干预措施: LALAK (Procedure)

LALAK

Experimental

laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.

干预措施: Retrobulbar Block or General Anesthesia (Drug)

LALAK

Experimental

laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.

干预措施: optical coherence tomography (OCT) (Device)

LALAK

Experimental

laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.

干预措施: Topical Anesthesia (Drug)

LALAK

Experimental

laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.

干预措施: femtosecond laser (Device)

IEK

Active Comparator

Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.

干预措施: IEK (Procedure)

IEK

Active Comparator

Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.

干预措施: Retrobulbar Block or General Anesthesia (Drug)

IEK

Active Comparator

Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.

干预措施: femtosecond laser (Device)

结局指标

主要结局

BSCVA (Snellen chart)

时间窗: 24 months

A primary outcome measures will be BSCVA (Snellen chart)

intraoperative perforation rate

时间窗: 24 months

A primary outcome measure will be intraoperative perforation rate.

次要结局

  • postoperative refractive error(24 months)
  • topographic astigmatism(24 months)
  • interface clarity(24 months)
  • endothelial cell count(24 months)
  • complications(24 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Huang

Winston Chamberlain, MD, PhD, Assistant Professor of Ophthalmology

Oregon Health and Science University

相似试验